Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat HF
NCT05194111Phase 2Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Aug 2022
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sacubitril + valsartan in heart failure (HF) (3 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Feasibility of recruitment at 27 months and Tolerability of treatment at 27 months. Started Aug 2022; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05194111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194111.